

SparingVision to Participate in the 10th Annual Biotech Showcase in San Francisco, January 8 – 10, 2018

Paris, FR, January 8, 2018 - SparingVision is a biotechnology company focused on the discovering and development of an innovative, therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa, announces today that Florence Allouche Ghrenassia, President and Chief Executive Officer, will provide a corporate overview at the 10th Annual Biotech Showcase, being held January 8-10, 2018 at the Hilton San Francisco Union Square in San Francisco, California.

SparingVision is one of five private French biotech companies selected (out of nearly 250 companies) to present at Biotech Showcase.

10th Annual Biotech Showcase SparingVision Presentation Details

Date: Wednesday, January 10, 2018
Time: 11:45 am Pacific Time
Location: Hilton San Francisco Union Square, Franciscan C (Ballroom Level)

About SparingVision

SparingVision is a biotechnology company focused on the discovering and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing a drug candidate to treat retinitis pigmentosa, the most frequent inherited retinal degeneration. This genetic condition which turns to blindness has no cure at that day and affects 2 million patients worldwide. SparingVision is a spin-off of Vision Institute (Institut de la Vision, Paris) and is the winner and Grand Prix of the i-LAB 2017 French National Competition for Innovative Companies, and one of the 7 companies in the new Bpifrance accelerator for biotech companies, Hub Health Tech.

Contacts:

Florence Allouche Ghrenassia, Pharm D.
President and CEO
SparingVision
Phone: +33 6 51 28 11 39
Email: fag@sparingvision.com

Linda Dyson, MPH
Executive Vice President
LifeSci Public Relations
Phone: 973.986.5973
Email: linda@lifescipublicrelations.com